AR and prostate carcinoma: It inhibited AR-positive prostate cancer cell proliferation (LNCaP and CWR22Rv1) at 0.5 μM, while exerting minimal effects on AR-negative PC-3 cells and non-malignant RWPE-1 prostate epithelial cells.